2025 年 6 月养殖业务主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 福建傲农生物科技集团股份有限公司（以下简称"公司"）现将 2025 年 6 月养殖业务主要经营数据披露如下： 一、2025 年 6 月养殖业务主要经营数据 单位：万头 | 主要产品 | 销售量 | 库存量 | 销售量同比 增减（%） | 库存量同比 增减（%） | | --- | --- | --- | --- | --- | | 生猪 | 14.24 | 54.70 | +20.46 | +20.70 | 证券代码：603363 证券简称：傲农生物 公告编号：2025-078 福建傲农生物科技集团股份有限公司 福建傲农生物科技集团股份有限公司董事会 2025 年 7 月 8 日 单位：万头 月份 当月销售量 当年累计销售量 期末库存量 2024 年 6 月 11.82 138.03 45.32 2024 年 7 月 12.55 150.58 47.54 2024 年 8 月 11.83 162.41 50.69 2024 年 9 月 ...

证券代码：603363 证券简称：傲农生物 公告编号：2025-079 福建傲农生物科技集团股份有限公司 关于新增涉及诉讼、仲裁事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 案件所处的诉讼（仲裁）阶段：公司 2025 年 3 月 10 日至今新增诉讼（仲 裁）金额 20,115.33 万元，其中尚未结案诉讼、仲裁案件金额为 17,588.20 万元， 已结案诉讼、仲裁案件金额为 2,527.13 万元。 上市公司所处的当事人地位：原告、被告；申请人、被申请人等。 涉案的金额：公司 2025 年 3 月 10 日至今新增诉讼（仲裁）金额 20,115.33 万元。 是否会对上市公司损益产生负面影响：鉴于部分诉讼、仲裁案件尚未开 庭审理或尚未结案或尚未执行完毕，上述事项对公司本期利润或期后利润的影响 存在不确定性。敬请投资者理性投资，注意投资风险。 根据《上海证券交易所股票上市规则》有关规定，福建傲农生物科技集团股 份有限公司对公司及下属控股子公司（简称"公司"）2025 年 3 月 10 日至今新 ...

Group 1 - The core point of the announcement is that Aonong Biological (603363) reported a pig sales volume of 142,400 heads in June 2025, which represents a year-on-year increase of 20.46%, but a month-on-month decrease of 8.84% [1] - As of the end of June 2025, the company's pig inventory stood at 547,000 heads, reflecting a year-on-year increase of 20.70%, a month-on-month increase of 1.98%, and an increase of 6.64% compared to the end of December 2024 [1]

Core Viewpoint - The "9+5" industry is the main support for the high-quality economic development of Zhangzhou, with a focus on new industrialization and the cultivation of strategic emerging industries [1][28]. Economic Overview - Zhangzhou's GDP is projected to exceed 600 billion yuan, reaching 606.37 billion yuan in 2024, with a year-on-year growth of 6.1% [3]. - The primary industry added value is 61.50 billion yuan (3.7% growth), the secondary industry is 272.82 billion yuan (7.2% growth), and the tertiary industry is 272.05 billion yuan (5.4% growth) [3]. - Per capita GDP is 119,612 yuan, reflecting a 6.0% increase [3]. Industrial Structure - Zhangzhou is focusing on the "9+5" industry clusters, which include nine trillion-yuan industries such as food processing and petrochemicals, and five industries exceeding 500 billion yuan, including electronic information and digital services [11][13]. - The industrial added value of the nine major industries is expected to grow by 7.5% in 2024, with a growth of 8.8% in the first quarter of 2025 [28][17]. Investment and Infrastructure - In 2024, Zhangzhou added 1,987 fixed asset investment projects with a total investment of 224.54 billion yuan, marking an 8.5% year-on-year growth [7]. - Investment in the primary industry grew by 53.7%, while the secondary industry saw a 21.7% increase, with industrial investment specifically rising by 21.8% [7]. Foreign Trade - Zhangzhou's total import and export volume reached 127.68 billion yuan in 2024, a 4.9% increase from the previous year, with exports at 88.46 billion yuan (3.2% growth) and imports at 39.22 billion yuan (8.9% growth) [9]. - The actual use of foreign capital increased by 100.4% in 2024 [9]. Key Enterprises - As of the end of 2024, Zhangzhou has six A-share listed companies, including Pianzaihuang, Longxi Co., Zhangzhou Development, Aonong Bio, Wancheng Group, and Tailong Co. [23]. - The city has 949 enterprises with an output value exceeding 100 million yuan, with a 12.9% increase in added value [25]. Policy Support - Zhangzhou has implemented the "Thousand Billion Industry Cultivation Action Plan" to support the development of the "9+5" industry clusters, aiming for a scale industrial output value to exceed one trillion yuan by 2025 [13][28]. - The government is focusing on enhancing service levels and optimizing the business environment to support project construction and enterprise development [28].

Summary of Key Points Core Viewpoint - The company, Fujian Aonong Biological Technology Group Co., Ltd., has announced its guarantee situation, detailing the amounts and conditions under which it provides guarantees to its subsidiaries and industry partners. Group 1: Guarantee Overview - The company plans to provide guarantees totaling up to 800 million yuan to industry chain partners, including suppliers and cooperative farmers [1] - The maximum guarantee amount for subsidiaries with an asset-liability ratio below 70% is set at 1.5 billion yuan, while for those above 70%, it is also 1.5 billion yuan [1] - The company’s wholly-owned and holding subsidiaries can provide guarantees of up to 500 million yuan for other subsidiaries with an asset-liability ratio below 70% and 1 billion yuan for those above 70% [1] Group 2: Progress on Guarantees - As of May 31, 2025, the total guarantee balance provided to 185 industry chain partners is 146.4893 million yuan [2] - The top five guarantees provided to cooperative farmers are as follows: - First: 5 million yuan, with a one-year term and no overdue payments - Second: 5 million yuan, with a one-year term and overdue payments - Third: 5 million yuan, with a one-year term and overdue payments - Fourth: 4 million yuan, with a one-year term and no overdue payments - Fifth: 3.8 million yuan, with a one-year term and overdue payments [2] Group 3: Total Guarantee Amounts - As of May 31, 2025, the total external guarantees provided by the company and its wholly-owned and holding subsidiaries amount to 1.225109 billion yuan, which is 47.74% of the company's latest audited net assets [4] - The guarantees provided to wholly-owned and holding subsidiaries total 1.4762398 billion yuan, representing 57.53% of the company's latest audited net assets [4] - The guarantees among subsidiaries amount to 680.4983 million yuan, accounting for 26.52% of the company's latest audited net assets [4]

福建傲农生物科技集团股份有限公司 2025 年 5 月公司担保情况的公告 证券代码：603363 证券简称：傲农生物 公告编号：2025-077 截至 2025 年 5 月 31 日，公司及下属子公司为产业链合作伙伴提供的担保余 额前五名的情况如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、担保情况概述 福建傲农生物科技集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 3 月 28 日召开的第四届董事会第十二次会议和 2025 年 4 月 14 日召开的 2025 年第二次临时股东大会审议通过了《关于 2025 年度为产业链合作伙伴提供 担保的议案》、《关于 2025 年度公司及下属子公司相互提供担保的议案》，内 容包括： 1、同意公司及下属子公司 2025 年度为公司及下属子公司的下游客户、产业 链供应商、公司养殖放养业务的合作养户等产业链合作伙伴提供不超过 8 亿元的 担保。 2、同意公司及下属全资、控股子公司在 2024 年度继续相互提供担保，其中 公司为下属资产负债率低于 70%的子公司提供 ...

Core Points - The legal opinion letter confirms the compliance of the 2024 annual shareholders' meeting of Fujian Aonong Biological Technology Group Co., Ltd. with relevant laws and regulations [1][2][3] - The meeting was convened by the board of directors and followed the proper procedures for notification and voting [4][5][13] Group 1: Meeting Procedures - The notice for the 2024 annual shareholders' meeting was published 20 days prior, in accordance with the Company Law and Shareholders' Meeting Rules [2][4] - The meeting was held at the company's conference room, presided over by the chairman, Su Mingcheng, and utilized an online voting system [3][5] Group 2: Attendance and Voting - A total of 439 shareholders and their proxies attended the meeting, representing 859,421,183 shares, which is 39.2573% of the total voting shares [4][5] - The voting results indicated that all resolutions were passed with more than half of the voting rights present, and special resolutions received over two-thirds approval [7][9][13]

Meeting Details - The annual general meeting was held on June 24, 2025, at the Fujian Aonong Conference Room in Zhangzhou, Fujian Province [1] - The meeting was attended by shareholders representing 39.2573% of the total shares [1] - The voting method combined on-site and online voting, complying with the Company Law and Articles of Association [1] Voting Results - All non-cumulative voting proposals were approved with high support from A-shareholders, with approval rates ranging from 99.7291% to 99.7772% [2][3][4] - Specific voting results included: - Proposal 1: 857,499,602 votes in favor (99.7764%) [1] - Proposal 2: 857,438,802 votes in favor (99.7693%) [1] - Proposal 3: 857,380,702 votes in favor (99.7626%) [1] - Proposal 4: 857,371,914 votes in favor (99.7616%) [1] - Proposal 5: 857,276,502 votes in favor (99.7505%) [2] Cash Dividend Voting - The cash dividend proposal received unanimous support from shareholders holding more than 5% of ordinary shares, with 100% approval [4] - Among shareholders holding less than 1%, 84.0690% voted in favor, while 13.1555% opposed [4] Legal Compliance - The meeting and voting procedures were verified by lawyers, confirming compliance with legal regulations and the company's Articles of Association [4]

Core Viewpoint - The company held its 16th meeting of the 4th Board of Directors on June 24, 2025, where several key resolutions were passed to enhance corporate governance and investor relations [1][2][3]. Group 1: Corporate Governance Enhancements - The company approved the establishment of a "Market Value Management System" to improve investment value and enhance investor returns [2]. - The company revised the "Investor Relations Management System" to strengthen communication with investors and protect the rights of minority shareholders [2]. - The company updated the "Information Disclosure Management System" to ensure compliance with legal requirements and protect the interests of shareholders and creditors [3]. Group 2: Internal Reporting and Compliance - The company revised the "Major Information Internal Reporting System" to clarify information collection and management procedures [4]. - The company updated the "Insider Information Knowledge Person Registration Management System" to enhance confidentiality and prevent insider trading [5]. - The company revised the "Information Disclosure Suspension and Exemption Management System" to ensure compliance with disclosure obligations [5]. Group 3: Audit and Financial Reporting - The company revised the "Board Audit Committee Annual Report Work Regulations" to improve the quality of financial reporting and enhance the supervisory role of the audit committee [6]. - The company updated the "Major Error Responsibility Accountability System for Annual Report Disclosure" to increase accountability for disclosure accuracy [6]. - The company revised the "Fundraising Management Measures" to enhance the management and utilization of raised funds [7]. Group 4: Management and Operational Procedures - The company revised the "Board Secretary Work System" to clarify the responsibilities and procedures for the board secretary [7]. - The company updated the "Internal Audit System" to improve audit quality and risk control [8]. - The company revised the "Accountant Firm Selection System" to ensure the integrity of financial information and protect shareholder interests [9]. Group 5: Risk Management and Hedging - The company approved the "Hedging Business Management System" to regulate futures and derivatives trading [12]. - The company authorized a maximum trading margin and premium limit of RMB 140.05 million for hedging activities, with a maximum contract value of RMB 1.27 billion on any trading day [12].

福建傲农生物科技集团股份有限公司 信息披露暂缓与豁免管理制度 （2025 年 6 月修订） 福建傲农生物科技集团股份有限公司 信息披露暂缓与豁免管理制度 福建傲农生物科技集团股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第一条 为规范福建傲农生物科技集团股份有限公司（以下简称"公司"） 信息披露暂缓与豁免行为，保证公司依法合规履行信息披露义务，保护投资者的 合法权益，根据《中华人民共和国证券法》《上市公司信息披露暂缓与豁免管理 规定》《上海证券交易所股票上市规则》（以下简称《股票上市规则》）和《上 海证券交易所上市公司自律监管指引第 2 号——信息披露事务管理》等法律、法 规、规范性文件以及《福建傲农生物科技集团股份有限公司章程》（以下简称"公 司章程"）、《福建傲农生物科技集团股份有限公司信息披露事务管理制度》（以 下简称"《信息披露事务管理制度》"）等规定，制定本制度。 第二条 公司暂缓、豁免披露临时报告，在定期报告、临时报告中豁免披露 中国证监会和上海证券交易所规定或者要求披露的内容，适用本制度。 第三条 公司应当真实、准确、完整、及时、公平地披露信息，不得滥用暂 缓或者豁免披露规避信息披露义 ...